Tonix Pharmaceuticals Holding Corp. — Q1 2021 10-Q
Reporting period: Three months ended March 31, 2021. Tonix is a clinical-stage biopharmaceutical company; it reported no commercial products or revenue. Financial amounts below are in U.S. dollars.
Financial results and liquidity
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $15.3 million | $4.7 million; up 226% |
| General and administrative expense | $5.4 million | $2.6 million; up 108% |
| Total operating expenses / operating loss | $20.7 million | $7.3 million |
| Net loss | $20.7 million | $7.3 million |
| Net loss per share, basic and diluted | $0.07 | $0.37 |
| Cash used in operating activities | $21.1 million | $9.3 million |
| Cash and cash equivalents at period-end | $164.2 million | $77.1 million at Dec. 31, 2020 |
Cash equivalents included $100.4 million in money-market funds; restricted cash was $0.24 million. Working capital was $167.1 million. Total assets were $183.5 million and total liabilities were $6.6 million, including $1.0 million of lease liabilities. The filing reports no conventional borrowings. With no revenue or gross profit, gross margin is not applicable; operating and net margins are not meaningful.
Material changes and financing
- Net loss increased by $13.4 million year over year, primarily as R&D spending rose for the TNX-102 SL fibromyalgia program, other clinical-development preparations, and COVID-19 vaccine work. G&A growth reflected higher compensation, legal and patent costs, financial reporting, investor relations, and insurance.
- Financing activities provided $108.7 million in cash, mainly from common-stock sales. January and February registered offerings raised approximately $36.9 million and $65.0 million net, respectively; Q1 ATM sales added approximately $7.0 million gross.
- Common shares outstanding increased from 206.0 million at December 31, 2020 to 323.9 million at March 31, 2021. The company also reported 22.98 million outstanding options and 0.64 million warrants at quarter-end. The lower reported loss per share versus 2020 coincided with a much larger weighted-average share count; Q1 2020 also included $1.7 million of deemed dividends.
Outlook, risks, and notable items
- Management said Q1 cash resources and post-quarter equity proceeds were expected to fund operating and capital requirements through March 31, 2022, but not beyond. The filing nevertheless states that substantial doubt exists about the company’s ability to continue as a going concern and that additional financing will be needed. Another MD&A passage says the company will not have enough resources for the one-year period from filing; this wording appears inconsistent with the stated March 2022 runway.
- Management expects continued operating losses, higher R&D spending, clinical-trial costs, and investment in research and manufacturing facilities. It may need additional equity, debt, or partner funding; unavailable or unacceptable financing could force delays, reductions, or termination of programs. Further equity financing could dilute shareholders.
- Clinical and regulatory outlook included interim RALLY fibromyalgia data expected in Q3 2021 and topline data in Q1 2022; a planned Phase 3 PTSD study in Kenya in Q3 2021; and expected 2021 development steps for several other candidates. These are forward-looking expectations, not guaranteed outcomes. TNX-102 SL did not meet the primary endpoint in its Phase 3 PTSD RECOVERY trial.
- After quarter-end, Tonix licensed OyaGen’s sangivamycin antiviral program, agreeing to a low-seven-figure license fee, 2,752,294 shares, royalties, and contingent milestones. The company also reported subsequent ATM sales of 2.6 million shares for $3.2 million gross and raised the ATM authorization to $170 million.
- Tonix had approximately $30.0 million of commitments for future contract research organization work. It reported no material legal proceedings and stated that disclosure controls were effective; no material change in internal control over financial reporting was reported.
- Risks include clinical-trial and FDA-approval uncertainty, reliance on third parties, financing needs, patent protection and competition, COVID-19 impacts, and significant volatility in the common stock, including potential short squeezes.
Key facts for investors to verify
- Whether subsequent financing and the cash-burn rate support the company’s stated runway, given the filing’s conflicting one-year liquidity statements and going-concern warning.
- Progress, interim analysis terms, and timing for TNX-102 SL’s RALLY study, and follow-up plans after the unsuccessful PTSD RECOVERY primary endpoint.
- Actual R&D cash requirements, the timing of the approximately $30.0 million CRO commitments, and planned facility spending.
- Share dilution from offerings, ATM sales, outstanding options and warrants, and the equity consideration issued after quarter-end.
- Whether pipeline milestones and regulatory plans are achieved; all described candidates remain investigational and are not approved for marketing.